EVALUATION OF TOPICAL 0.1% TAZAROTENE CREAM IN THE TREATMENT OF PALMOPLANTAR PSORIASIS: AN OBSERVER-BLINDED RANDOMIZED CONTROLLED STUDY

Lignende værker

• Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac(®)) Cream 0.1%
  af: Sidgiddi, Srinivas, et al.
  Udgivet: (2019)
• Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
  af: Reddy V, et al.
  Udgivet: (2020-06-01)
• Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
  af: Reddy, Vidhatha, et al.
  Udgivet: (2020)
• Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream
  af: Bhatia, Neal D., et al.
  Udgivet: (2018)
• Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential
  af: Del Rosso, James Q., et al.
  Udgivet: (2019)